The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...
Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i).
An investigation led by Brigham and Women's Hospital finds empagliflozin (sold as Jardiance) may reduce the risk of diabetic ...
They do this by blocking the action of an enzyme called dipeptidyl peptidase-4 (DPP-4). This enzyme breaks down hormones that reduce blood sugar levels. By interfering with this process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback